Received Jun 20, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | 2 | T5D73 | — |
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
inadvertent administration of 1st dose; inadvertent administration of 2nd dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of inappropriate age at vaccine administration in a 17-year-old male patient who received HBV (Engerix B) (batch number T5D73, expiry date 10-APR-2027) for prophylaxis. Co-suspect products included HBV (Engerix B) for prophylaxis. On 24-JAN-2025, the patient received the 2nd dose of Engerix B. On an unknown date, the patient received the 1st dose of Engerix B. On 24-JAN-2025, an unknown time after receiving Engerix B and Engerix B, the patient experienced inappropriate age at vaccine administration (Verbatim: inadvertent administration of 2nd dose). On an unknown date, the patient experienced inappropriate age at vaccine administration (Verbatim: inadvertent administration of 1st dose). The outcome of the inappropriate age at vaccine administration and inappropriate age at vaccine administration were not applicable. Additional Information: GSK receipt date: 13-JUN-2025 Other HCP reported that the inadvertent administration of two adult doses to a 17-year-old male patient, which led to inappropriate age at vaccine administration. He wanted to know how to proceed, and if the same vaccine could be used or a vaccine change is needed for completing the third dose. Second dose was administered on 24 January 2025, and third dose is scheduled as for 24 June 2025.